Celldex Therapeutics (CLDX) is a clinical-stage biotechnology company that focuses on developing targeted therapies for rare ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of ...

Leerink Partners analyst Thomas Smith maintained a Buy rating on Celldex (CLDX – Research Report) on October 14 and set a price target of ...

They can be big or small, vary in shape, and can appear anywhere on the body. Hives typically pop up as a result of an allergic reaction to food items or medicines. They can be acute, and last less ...

Some people get hives occasionally and they clear up quickly without any issue. However, some people develop chronic hives that can be harder to treat. Cold compresses, OTC anti-itch creams, and ...

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor ...

LEO Pharma Inc., a global leader in medical dermatology, has launched Talk to the Hand, a disease awareness campaign for healthcare providers that highlights the risk factors, symptoms, and physical ...

ACELYRIN, INC. (SLRN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Derek ...